Envista Holdings Corporation (NYSE:NVST) Receives Average Rating of “Hold” from Analysts

Shares of Envista Holdings Corporation (NYSE:NVST) have received a consensus recommendation of “Hold” from the fifteen analysts that are presently covering the company, MarketBeat.com reports. Nine investment analysts have rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 12 month price target among analysts that have covered the stock in the last year is $28.6667.

NVST has been the topic of several research analyst reports. Barclays cut their price target on Envista from $34.00 to $32.00 and set an “overweight” rating on the stock in a research report on Thursday, June 11th. Zacks Research downgraded Envista from a “strong-buy” rating to a “hold” rating in a report on Monday, April 6th. Morgan Stanley raised their target price on shares of Envista from $19.00 to $21.00 and gave the stock an “equal weight” rating in a research report on Friday, April 24th. Wall Street Zen cut shares of Envista from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 9th. Finally, Robert W. Baird upped their price target on shares of Envista from $30.00 to $31.00 and gave the company an “outperform” rating in a research report on Thursday, May 7th.

Envista Stock Up 1.5%

NVST opened at $27.59 on Friday. The business’s 50-day simple moving average is $24.85 and its 200-day simple moving average is $25.25. The company has a debt-to-equity ratio of 0.47, a quick ratio of 2.06 and a current ratio of 2.44. Envista has a one year low of $18.77 and a one year high of $30.42. The stock has a market capitalization of $4.49 billion, a P/E ratio of 67.28, a price-to-earnings-growth ratio of 1.54 and a beta of 0.86.

Envista (NYSE:NVST) last posted its earnings results on Wednesday, May 6th. The company reported $0.36 earnings per share for the quarter, beating the consensus estimate of $0.31 by $0.05. The business had revenue of $705.50 million during the quarter, compared to the consensus estimate of $680.03 million. Envista had a return on equity of 7.11% and a net margin of 2.41%.The business’s quarterly revenue was up 14.4% on a year-over-year basis. During the same period in the previous year, the business earned $0.24 EPS. Envista has set its FY 2026 guidance at 1.350-1.450 EPS. Analysts anticipate that Envista will post 1.42 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. Edgestream Partners L.P. purchased a new stake in shares of Envista in the first quarter valued at about $2,619,000. Amundi grew its holdings in shares of Envista by 8.7% during the first quarter. Amundi now owns 184,575 shares of the company’s stock worth $4,683,000 after buying an additional 14,739 shares during the last quarter. California State Teachers Retirement System grew its holdings in shares of Envista by 22.6% during the first quarter. California State Teachers Retirement System now owns 194,212 shares of the company’s stock worth $4,927,000 after buying an additional 35,848 shares during the last quarter. Quantinno Capital Management LP increased its position in Envista by 38.8% in the 1st quarter. Quantinno Capital Management LP now owns 2,694,970 shares of the company’s stock valued at $68,371,000 after acquiring an additional 753,474 shares during the period. Finally, SummitTX Capital L.P. acquired a new position in Envista in the 1st quarter valued at about $4,268,000.

Envista Company Profile

Envista Holdings Corporation is a global dental products company that develops, manufactures and markets a broad portfolio of dental consumables, equipment and technology solutions. Headquartered in Brea, California, Envista serves dental practitioners, specialists and laboratories in more than 150 countries. The company’s offerings span implant, orthodontic, endodontic and restorative product lines as well as digital imaging systems and practice management software.

Envista’s product brands include Nobel Biocare for dental implants and restorative solutions, Ormco for orthodontic appliances and treatment systems, Kerr for restorative and endodontic materials, KaVo for dental imaging and handpieces, and Vista for surgical drills and instruments.